Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Public ClinicalTrials.gov record NCT05231122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.
Study identification
- NCT ID
- NCT05231122
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 80 participants
Conditions and interventions
Conditions
- Ovarian Clear Cell Adenocarcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Fallopian Tube Serous Adenocarcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Serous Adenocarcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological
- Bevacizumab Biological
- Pembrolizumab Biological
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2024
- Primary completion
- Mar 14, 2027
- Completion
- Mar 14, 2027
- Last update posted
- Aug 13, 2026
2024 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | Recruiting |
| M D Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05231122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05231122 live on ClinicalTrials.gov.